Machine learning based personalized drug response prediction for lung cancer patients
Authors:
Open Access
- 7 November 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Abstract
Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been developed against EGFR and show encouraging results for survival rate and quality of life. However, drug resistance may affect treatment plans and treatment efficacy may be lost after about a year. Predicting the response to EGFR-TKIs for EGFR-mutated lung cancer patients is a key research area. In this study, we propose a personalized drug response prediction model (PDRP), based on molecular dynamics simulations and machine learning, to predict the response of first generation FDA-approved small molecule EGFR-TKIs, Gefitinib/Erlotinib, in lung cancer patients. The patient’s mutation status is taken into consideration in molecular dynamics (MD) simulation. Each patient’s unique mutation status was modeled considering MD simulation to extract molecular-level geometric features. Moreover, additional clinical features were incorporated into machine learning model for drug response prediction. The complete feature set includes demographic and clinical information (DCI), geometrical properties of the drug-target binding site, and the binding free energy of the drug-target complex from the MD simulation. PDRP incorporates an XGBoost classifier, which achieves state-of-the-art performance with 97.5% accuracy, 93% recall, 96.5% precision, and 94% F1-score, for a 4-class drug response prediction task. We found that modeling the geometry of the binding pocket combined with binding free energy is a good predictor for drug response. However, we observed that clinical information had a little impact on the performance of the model. The proposed model could be tested on other types of cancers. We believe PDRP will support the planning of effective treatment regimes based on clinical-genomic information. The source code and related files are available on GitHub at: https://github.com/rizwanqureshi123/PDRP/.Keywords
This publication has 67 references indexed in Scilit:
- Personalized prediction of EGFR mutation-induced drug resistance in lung cancerScientific Reports, 2013
- Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized BornJournal of Chemical Theory and Computation, 2012
- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trialTrials, 2010
- A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical programTrials, 2010
- Alpha Shapes Applied to Molecular Shape Characterization Exhibit Novel Properties Compared to Established Shape DescriptorsJournal of Chemical Information and Modeling, 2009
- Quantitative Prediction of Fold Resistance for Inhibitors of EGFRBiochemistry, 2009
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- The COSMIC (Catalogue of Somatic Mutations in Cancer) database and websiteBritish Journal of Cancer, 2004
- Molecular dynamics simulations of biomoleculesNature Structural & Molecular Biology, 2002
- The Protein Data BankNucleic Acids Research, 2000